Brief: Vir Biotechnology Maintains Operating Accounts At SVB With About $220 Mln As Of March 10
13/03/2023 11:09
March 13 (Reuters) - SVB Financial Group SIVB.O :
* VIR BIOTECHNOLOGY INC - MAINTAINS OPERATING ACCOUNTS AT
SVB WITH
APPROXIMATELY $220 MILLION AS OF MARCH 10, 2023
Further company coverage: SIVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO